Glycosaminoglycans (GAGs) are complex biopolymers that play important roles in inflammation, coagulation, angiogenesis, cell adhesion and viral invasion by interacting with several different proteins.1,2 Structurally, GAGs are built up of several different sulfated disaccharide units.3 Specific GAG sequences that uniquely recognize their cognate proteins exist. Such specificity typically arises from the binding of unique sulfation patterns on the linear GAG chain to highly electropositive protein domains. Thus, these highly charged, sulfated biopolymers potentially represent a new class of therapeutics. Yet, the major stumbling block to the development to these agents is their extremely complicated and tedious chemical synthesis. We hypothesized that replacing the saccharide skeleton with an equivalent non-saccharide and readily synthesized organic skeleton would usher in an era of new, GAG-based therapeutics. This challenge has been addressed on two fronts, computational design and chemical synthesis, by focusing on the heparin pentasaccharide-antithrombin system that represents an exhaustively studied model GAG-protein system. With respect to chemical synthesis, a microwave-based synthetic procedure that can rapidly introduce multiple sulfate groups on a poly-hydroxyl substrate within minutes was developed.4 Using this method, the synthesis of a previously designed activator (IAS5), which otherwise proved to be problematic, was successfully completed. Biochemical screening of IAS5 and its analogs revealed that these molecules could activate antithrombin up to 30-fold in comparison to the 300-fold activation by the heparin pentasaccharide. In an effort to develop more potent antithrombin activators, a new method to predict high affinity GAG sequences for a given GAG-binding protein based on combinatorial virtual-library screening was developed.5 This combinatorial virtual-library screening method was applied to a library of 24,576 non-saccharide, sulfated molecules that were created using the structure of IAS5 as a template. Thirty seven‘hits’ that had common structural features were identified from this study. Interestingly, all these ‘hits’ bind to antithrombin similarly and orient the 4 negative charges identical to the corresponding groups in the heparin pentasaccharide. The synthesis of selected targets is currently in progress and several synthetic steps have already been optimized.

Thyroid disruptions by xenobiotics have been associated with a broad spectrum of severe adverse human health effects, such as impaired brain development and metabolic syndrome. Ingestion of indoor dust and contact with industrial chemicals are two significant human exposure routes of thyroid hormone disrupting chemicals (THDCs), raising serious concerns for human health. However, it is a laborious and costly process to identify THDCs using conventional experimental methods, due to the number of chemicals in commerce and the varieties of potential disruption mechanisms. In this thesis, we are aimed at in silico identification of novel THDCs targeting transthyretin (TTR) and thyroid hormone receptor (THR) among dust contaminants and commonly used industrial chemicals. In vitro assays were used to validate the in silico prediction results. Co-crystallization and molecular dynamics (MD) simulations were applied to reveal binding modes of THDCs at the studied biological targets and to explain their intermolecular recognition. The main findings presented in this thesis are: 1. Over 144 environmental pollutants have been confirmed as TTR-binders in vitro and these cover a wide range of environmental pollutants and show distinct chemical profiles including a large group of halogenated aromatic compounds and a second group of per- and polyfluoroalkyl substances. (Paper I) 2. In total 485 organic contaminants have been reported to be detected in household dust. The developed QSAR classification model predicted 7.6% of these dust contaminants and 53.1% of their metabolites as potential TTR-binders, which emphasizes the importance of metabolic bioactivation. After in vitro validation, four novel TTR binders with IC50 ≤ 10 µM were identified, i.e. perfluoroheptanesulfonic acid, 2,4,2',4'-tetrahydroxybenzophenone (BP2), 2,4,5-trichlorophenoxyacetic acid, and 3,5,6-trichloro-2-pyridinol. (Paper II) 3. The development of a robust structure-based virtual screening (VS) protocol resulted in the prediction of 31 dust contaminants as potential binders to THRβ1 including musk compounds, PFASs, and bisphenol A derivatives. The in vitro experiments confirmed four compounds as weak binders to THRβ1, i.e. 2,4,5-trichlorophenoxyacetic acid, bisphenol A (3-chloro-2-hydroxypropyl) (2,3-dihydroxypropyl) ether, 2,4,2',4'-tetrahydroxybenzophenone, and 2,4-dichlorophenoxyacetic acid. (Paper III) 4. We revealed the binding conformations of perfluorooctanesulfonic acid, perfluorooctanoic acid, and BP2 in the thyroxine binding sites (TBSs) of TTR by co-crystallizing TTR with the three compounds. A VS protocol was developed based on the TTR complex structures that predicted 192 industrial chemicals as potential binders to TTR. Seven novel TTR binders were confirmed by in vitro experiments including clonixin, 2,6-dinitro-p-cresol (DNPC), triclopyr, fluroxypyr, bisphenol S, picloram, and mesotrione. We further co-crystallized TTR with PBS, clonixin, DNPC, and triclopyr, and their complex structures showed that the compounds bind in the TBSs as proposed by the VS protocol. In summary, 13 indoor dust contaminants and industrial chemicals were identified as THDCs using a combination of in silico and in vitro approaches. To the best of our knowledge, none of these compounds has previously been reported to bind to TTR or THR. The identifications of these THDCs improve our understanding on the structure-activity relationships of THDCs. The crystal structures of TTR-THDC complexes and the information on THDC-Target intermolecular interactions provide a better understanding on the mechanism-of-actions behind thyroid disruption. The dataset compiled and in silico methods developed serve as a basis for identification of more diverse THDCs in the future and a tool for guiding de novo design of safer replacements.

Le processus de découverte de médicaments a un succès limité malgré tous les progrès réalisés. En effet, on estime actuellement que le développement d'un médicament nécessite environ 1,8 milliard de dollars américains sur environ 13 ans. Nous nous concentrons dans cette thèse sur des approches statistiques qui criblent virtuellement un grand ensemble de composés chimique contre un grand nombre de protéines. Leurs applications sont polyvalentes : elles permettent d’identifier des candidats médicaments pour des cibles thérapeutiques connues, d’anticiper des effets secondaires potentiels, ou de proposer de nouvelles indications thérapeutiques pour des médicaments connus. Cette thèse est conçue selon deux cadres d'approches de criblage virtuel : les approches dans lesquelles les données sont décrites numériquement sur la base des connaissances des experts, et les approches basées sur l'apprentissage automatique de la représentation numérique à partir du graphe moléculaire et de la séquence protéique. Nous discutons ces approches et les appliquons pour guider la découverte de médicaments. / The rational drug discovery process has limited success despite all the advances in understanding diseases, and technological breakthroughs. Indeed, the process of drug development is currently estimated to require about 1.8 billion US dollars over about 13 years on average. Computational approaches are promising ways to facilitate the tedious task of drug discovery. We focus in this thesis on statistical approaches which virtually screen a large set of compounds against a large set of proteins, which can help to identify drug candidates for known therapeutic targets, anticipate potential side effects or to suggest new therapeutic indications of known drugs. This thesis is conceived following two lines of approaches to perform drug virtual screening : data-blinded feature-based approaches (in which molecules and proteins are numerically described based on experts' knowledge), and data-driven feature-based approaches (in which compounds and proteins numerical descriptors are learned automatically from the chemical graph and the protein sequence). We discuss these approaches, and also propose applications of virtual screening to guide the drug discovery process.

O Mal de Alzheimer é a causa mais importante de demência em idosos. A progressão dos sintomas da doença está associada com modificações estruturais nas sinapses colinérgicas em determinadas regiões cerebrais e, consequentemente, à diminuição do potencial de neurotransmissão colinérgica. Desta forma, o aumento da capacidade de neurotransmissão colinérgica constitui o mecanismo fundamental dos fármacos utilizados para o tratamento do Mal de Alzheimer. Atualmente, o único tratamento clínico eficaz para o Mal de Alzheimer (MA) é a utilização de inibidores da acetilcolinesterase (AChE). Os anticolinesterásicos são os fármacos mais promissores desenvolvidos até hoje, pois é a única classe terapêutica que mostrou melhora nos sintomas cognitivos do MA. Para esse projeto, foram utilizadas diferentes técnicas de modelagem molecular como estratégia de planejamento racional de fármacos, tendo como base os inibidores de Acetilcolinesterase (AChE) descritos na literatura além dos que possuem estruturas depositadas no PDB, incluindo alguns que já vêm sendo utilizados no tratamento do Mal de Alzheimer. O objetivo foi planejar e testar novos potenciais inibidores desse alvo terapêutico, na tentativa de obter e futuramente otimizar novos protótipos como futuros candidatos a fármacos em Mal de Alzheimer. Os objetivos estendem-se a propostas de novos potenciais protótipos, selecionados de bases de dados de compostos comerciais contendo propriedades de fármacos. Os screenings virtuais foram tendenciados às estruturas dos inibidores já reportados da literatura bem como ao padrão farmacofórico comum a eles, a ser modelado. / Alzheimer\'s disease is the leading cause of dementia in the elderly. The progression of symptoms is associated with structural changes in cholinergic synapses in specific brain regions and consequentely to decrease the potential of cholinergic neurotransmission. Thus, the increased capacity of cholinergic neurotransmission is the fundamental mechanism of the drugs used to treat Alzheimer\'s disease. Currently, the only effective clinical treatment for Alzheimer\'s (MA) is the use of inhibitors of acetylcholinesterase (AChE). Cholinesterase inhibitors are the most promising drugs developed so far, it is the only therapeutic class that showed improvement in cognitive symptoms of MA. For this project, we used different techniques of molecular modeling as a strategy for rational design of drugs based on inhibitors of acetylcholinesterase (AChE) in the literature than those which have structures deposited in the PDB, including some that have already been used in the treatment Alzheimer\'s disease.The objective was to design and test new potential inhibitors of therapeutic target in attempts to obtain and optimize future new prototypes as future drug candidates in Alzheimer\'s disease. The goals extend to proposals from potential new prototypes, selected from databases of commercial compounds containing properties of drugs. The virtual screenings were trends to structures of the inhibitors already reported in the literature as well as the pharmacophoric pattern common to them, to be modeled.

A Apis mellifera é um inseto pertencente à ordem Himenóptera, família Apidae, possui ocorrência cosmopolita e grande importância ecológica, econômica e médica. As subespécies hibridas que ocorrem no Brasil possuem características predominantemente africanas e passaram a ser conhecidas como abelhas africanizadas. As principais características das abelhas africanizadas são o comportamento agressivo, boa resistência a doenças, alta produção de mel e o aumento da frequência de enxameamentos, que tem causado preocupação por estar acompanhado, de aumento no número de acidentes. A agressividade e o aumento da frequência do exameamento fazem com que elas estejam repetidamente envolvidas em ataques massivos a humanos e animais, tornando esse tipo de envenenamento um problema de saúde pública. A busca de tratamento para o envenenamento tem sido alvo de diversas pesquisas. De uma forma geral, os tratamentos atuam sobre os efeitos causados pelo veneno (medicamentos) ou sobre os componentes do veneno (soros e inibidores). Os principais componentes do veneno são a fosfolipase A2 (PLA2) e a melitina. A PLA2 é uma das principais proteínas do veneno, que degrada a membrana plasmática das células e tem o seu efeito potencializado pela presença da melitina. A PLA2 da Apis mellifera possui a estrutura protéica determinada e sítio ativo identificado. Essas características qualificam a PLA2 como potencial alvo de estudos de planejamento de fármacos. A estratégia de planejamento de fármacos tem como objetivo acelerar o processo de identificação de ligantes, contribuindo para o processo da descoberta de fármacos. Este trabalho teve como objetivo identificar in silico potenciais inibidores contra a PLA2 de Apis mellifera, avaliar in vitro e in vivo a potencial atividade inibitória dos compostos selecionados e identificar a citotoxicidade in vitro dos compostos. A estrutura da PLA2 foi obtida da base de dados (PDB) e a busca de compostos feita das bibliotecas Maybridge e Chembridge. A triagem virtual foi realizada com o auxilio do programa GOLD. Os compostos identificados (22 da Maybridge e 68 da Chembridge) pelos programas GOLD foram filtrados com o uso das ferramentas computacionais para seleção dos compostos com melhores interações no sítio ativo. Os parâmetros utilizados como filtros foram as análises das ligações químicas e os campos de interação molecular. Os compostos selecionados (20 da Maybridge e 29 da Chembridge) foram submetidos a um grupo de programas computacionais para predição de características físico-químicas (drug-like), toxicidade e atividade biológica dos ligantes. Os resultados das predições sugeriram que os compostos da Chembridge fossem utilizados nas análises experimentais. Os compostos da biblioteca Chembridge foram adquiridos (29 do total de 49 compostos). Os compostos tiveram as suas potenciais atividades inibitórias avaliadas in vitro e in vivo. A atividade fosfolipásica foi avaliada para os 29 compostos e 11 apresentaram atividade inibitória contra PLA2. Os 11 compostos foram avaliados in vivo com o experimento de indução de edema e 5 compostos conseguiram reduzir o edema. Os compostos foram avaliados em relação a citoxicidade que poderiam causar. A citotoxicidade in vitro foi calculada para 3 compostos dos 5 inibidores obtidos. O resultado do experimento identificou 2 compostos como citotóxicos e 1 com menor citotoxicidade. Apesar da citotoxicidade identificada, mais estudos devem ser realizados para determinar a concentração inibitória não tóxica. Portanto, o trabalho identificou 5 potenciais inibidores específicos contra a PLA2 de Apis mellifera. / Apis mellifera is an insect belonging to the order Hymenoptera , Apidae family , has cosmopolitan occurrence and major ecological , economic, and medical . The hybrid subspecies that occur in Brazil have predominantly African features and came to be known as Africanized bees . The main characteristics of Africanized bees are aggressive behavior , good disease resistance, high honey production and increased frequency of enxameamentos , which has caused concern to be monitored , the increase in the number of accidents . The aggressiveness and increased frequency of exameamento cause they are repeatedly involved in massive human and animal attacks , making this kind of poisoning a problem of public health. The search for treatments for poisoning has been the subject of several studies . In general , treatments act on the effects caused by poison ( drug ), or the components of poison ( sera and inhibitors) . The main components of the venom are A2 ( PLA2 ) and phospholipase melittin . PLA2 is a major venom proteins , which degrades the plasma membrane of the cells and its effect is potentiated by the presence of melittin . The Apis mellifera PLA2 has determined the protein structure and active site identified . These characteristics qualify PLA2 as a potential target for drug design studies . The strategy for drug design aims to accelerate the identification of ligands , contributing to the process of drug discovery . This study aimed to identify in silico potential inhibitors of PLA2 Apis mellifera , in vitro and in vivo the potential inhibitory activity of selected compounds and identify the in vitro cytotoxicity of the compounds . The structure of PLA2 was obtained from the database (PDB ) and the search for compounds made from Maybridge Chembridge and libraries. The virtual screening was done with the aid of the GOLD program. The identified compounds ( 22 and 68 of the Maybridge Chembridge ) by GOLD programs were filtered with the use of computational tools for the selection of compounds with better interactions in the active site . The parameters used were as filters analyzes of chemical bonds and the fields of molecular interaction. The selected compounds ( 20 and 29 of the Maybridge Chembridge ) were submitted to a group of computer programs for the prediction of physico- chemical characteristics ( drug -like) , toxicity and biological activity of the ligands . The results of the predictions suggest that the compounds of Chembridge were used in experimental analysis . The compounds were obtained from Chembridge library (29 of 49 compounds). The compounds had their potential inhibitory activity evaluated in vitro and in vivo . The phospholipase activity was assessed for compounds 29 and 11 showed inhibitory activity against PLA2 . The 11 compounds were evaluated in vivo experiment with the induction of edema and 5 compounds were able to reduce edema . The compounds were evaluated for cytotoxicity that could cause . The in vitro cytotoxicity was calculated for three of the compounds obtained 5 inhibitors . The result of the experiment identified as cytotoxic compounds 2 and 1 with lower cytotoxicity . Despite the cytotoxicity identified , further studies should be conducted to determine the non-toxic inhibitory concentration . Therefore, the study identified 5 potential specific inhibitors of PLA2 Apis mellifera.

As doenças tropicais negligenciadas, que atingem as populações mais carentes do mundo, representam em termos humanitários e socioeconômicos uma grande preocupação global. As tripanossomíases estão entre as doenças parasitárias mais importantes, e, particularmente, a tripanossomíase africana, ou doença do sono, destaca-se como uma grave condição de saúde, causada pelo parasita unicelular Trypanosoma brucei. Dentre os principais alvos metabólicos considerados para o desenvolvimento de novos fármacos para o tratamento das tripanossomíases, a glicólise recebe especial atenção em função de seu papel vital no processo de produção de ATP para o parasita que vive na corrente sanguínea. Esta tese de doutorado tem como objetivo identificar novos candidatos a inibidores da enzima aldolase (EC 4.1.2.13) da via glicolítica de T. brucei. Considerando-se que o alvo macromolecular em questão é validado para o planejamento de fármacos, inibidores desta enzima são candidatos a novos agentes quimioterápicos. Este trabalho explora a integração de métodos experimentais e computacionais através de estratégias de planejamento de fármacos baseado na estrutura do receptor (SBDD, na sigla inglesa para structure-based drug design) e na estrutura do ligante (LBDD, na sigla inglesa para ligand-based drug design) para a identificação de inibidores da enzima alvo. Foram produzidos resultados significativos, tais como a identificação através de triagens virtuais em larga escala de novas moléculas capazes de inibir a atividade da aldolase. Adicionalmente, destaca-se a obtenção de protocolos de expressão, purificação e cristalização para a enzima alvo. Como parte da estratégia de identificação de novos inibidores da aldolase, foram desenvolvidos modelos de QSAR 2D e 3D e estudos de dinâmica molecular. / Neglected tropical diseases, which affect the poorest populations across the developing world, are a major global concern. The trypanosomiases are amongst the most serious neglected tropical diseases, and particularly, African trypanosomiasis (sleeping sickness), caused by the unicellular parasite Trypanosoma brucei, appears as a fatal condition. The glycolytic pathway emerges as a promising target among the metabolic pathways for the development of new drugs, due to its essential role in the ATP generating process in the bloodstream form of the parasite. The goal of this work is to identify new inhibitors for the glycolytic enzyme aldolase (EC 4.1.2.13) from Trypanosoma brucei. Inhibitors of this enzyme are drug candidates with high potential for clinical development, as the respective target enzyme was validated as a molecular target for the therapy of trypanosomiasis. The strategy employed in this study includes the integration of SBDD (structure-based drug design) and LBDD, (ligand-based drug design) for the identification of inhibitors of the target enzyme, through the combination of computational and experimental methodologies. Significant results were obtained, such as the identification of new small molecule inhibitors of the aldolase enzyme through high-throughput virtual screening. Additionally, it is highlighted the standardization of expression, purification and crystallization protocols for the target enzyme. As a component of the strategy for the identification of novel aldolase inhibitors, 2D and 3D QSAR models were developed, as well as molecular dynamics studies.

A doença de Chagas afeta milhões de pessoas e os fármacos existentes não são seguros e apresentam eficácia limitada. Muitos produtos naturais mostraram efeitos inibitórios contra uma enzima importante para a sobrevivência do Trypanosoma cruzi, a gliceraldeído-3-fosfato desidrogenase (GAPDH). Dentre esses produtos naturais destacam-se aqueles da classe dos flavonoides, sendo que um deles, o tilirosídeo, mostrou-se interessante por inibir a enzima com valores de IC50 e Ki iguais a 46 e 25 µM, respectivamente, além de ter sido eficaz contra a cepa do T. cruzi resistente a fármacos (cepa Y) mostrando um valor de IC50 igual a 770 µM. Com objetivo de identificar novos potenciais inibidores da TcGAPDH baseados no tilirosídeo foram empregados métodos computacionais nos quais combinaram-se duas diferentes estratégias: os ensaios virtuais baseados na estrutura do ligante (LBVS) e os ensaios virtuais baseados na estrutura do receptor (SBVS). Os compostos que se ajustaram ao sítio catalítico da enzima e preditos para interagir de forma efetiva com o alvo foram adquiridos e testados contra a TcGAPDH. Os estudos de inibição enzimática foram realizados utilizando as técnicas de calorimetria de titulação isotérmica e espectroscopia de fluorescência obtendo como resultados as constantes de inibição dos compostos selecionados e seus modos de inibição. Dois flavonoides, o Nequimed 214 e o Nequimed 215 inibiram a TcGAPDH na mesma grandeza que o composto de partida, o tilirosídeo, mas como possuem cerca da metade da massa molecular, houve grande aumento da eficiência do ligante. A partir dessa informação, foram selecionados uma segunda geração de compostos preditos a interagir com a TcGAPDH. Deste modo, foram adquiridos bioisósteros de flavonoides que foram testados contra essa enzima, sendo que dois dos mesmos mostraram-se ativos e com alta eficiência do ligante. Foram adquiridos também compostos pertencentes à classe das hidantoínas, rodaninas, tio-hidantoínas e pirrolidina-2,4-dionas sendo que muitos dos mesmos foram ativos e mostraram os maiores valores de eficiência do ligante já relatados para a TcGAPDH, tornando-os excelentes candidatos para otimização molecular. Os resultados obtidos sugerem que vários inibidores possuem inibição não competitiva com relação ao substrato G3P. Os inibidores mais potentes foram testados contra a GAPDH de humanos e não foi verificada seletividade relevante. / Chagas disease affects millions of people worldwide. The available drugs are not safe and show limited efficacy. Many natural products inhibit the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an important Trypanosoma cruzi enzyme. Among them, flavonoids have stood out and one of them, the tiliroside, inhibited the enzyme with IC50 and Ki values of 46 and 25 µM, respectively. Furthermore, unpublished results showed that this compound was effective against the drug-resistant strain of T. cruzi (Y strain) with IC50 value of 770 µM. In order to select potential inhibitors of TcGAPDH based on the tiliroside structure, computational methods were used combining two different strategies, the ligand-based virtual screening (LBVS) and the structure-based virtual screening (SBVS). The compounds predicted to interact effectively with the target and fit into the active site of the enzyme were purchased and tested. Enzyme inhibition studies were performed using isothermal titration calorimetry and fluorescence spectroscopy from which the constants and mode of inhibition of the compounds were determined. Two of the tested flavonoids, Nequimed 214 and Nequimed 215, showed inhibition activity against TcGAPDH in the same magnitude values as the starting compound, the tiliroside, in spite of their lower molecular weight, thus greatly enhancing the ligand efficiency (LE). These data prompted us to search for some flavonoid bioisosters that were obtained and tested against this enzyme, and two of them proved to be active with high ligand efficiencies. We also purchased compounds belonging to the class of hydantoins, pyrrolidine-2,4-dione, thio-hydantoin and rhodanine. Many of them were active at low micromolar concentration range and exhibited the highest ligand efficiencies ever reported for this enzyme, therefore becoming excellent candidates for molecular optimization. The obtained results suggest that most of inhibitors tested behave as non-competitive inhibitors with respect to the G3P substrate. The most potent inhibitors were tested against human GAPDH and relevant selectivity was not observed.

A doença de Alzheimer (DA) é uma desordem neurodegenerativa progressiva, caracterizada pela perda de neurônios corticais e subcorticais. Padrões patológicos da doença de Alzheimer incluem a presença de lesões neurofibrilares que consistem no acúmulo da proteína ?- amilóide e dos emaranhados neurofibrilares, decorrentes da hiperfosforilação da proteína Tau. Apenas dois grupos principais de fármacos são utilizados para o tratamento da DA, os inibidores colinesterásicos e antagonistas do receptor N-metil-D-aspartato. Entretanto, a fosforilação de proteínas pelas proteínas cinases constituem um dos principais mecanismos pelos quais as células se utilizam para regular seu metabolismo e demais funções e desequilíbrios nestas atividades estão relacionados a uma infinidade de doenças. O número elevado de isoformas de proteínas cinases 1 (CK1) encontradas na DA e sua associação em marcadores de lesões neurodegenerativas indicam sua participação nas etapas finais da degeneração, comum tanto à DA quanto a outras desordens neurodegenerativas. A abordagem da proteína CK1 como alvo terapêutico para a DA é promissora uma vez que os compostos usuais utilizados para diminuir a produção de ?-amilóide também bloqueiam a quebra de outras proteínas, causando graves efeitos colaterais. Cada vez mais as ferramentas de bioinformática vêm sendo utilizadas como auxílio na redução de custos e tempo para as pesquisas. Dentre estas técnicas destaca-se a triagem virtual, que reúne um conjunto de técnicas utilizadas de forma sequencial com o objetivo de selecionar compostos protótipos para os alvos desejados. Neste trabalho, foram utilizadas técnicas de triagem virtual baseada em ligantes e estrutura, a partir de uma base de 500 mil compostos, selecionando 35 compostos com perfil de atividade inibitória para a enzima CK1. Destes, os compostos 24, 25, 36, 39 41 e 42 apresentaram resultados significativos com relação ao potencial de inibição da enzima CK1?. Entre aqueles que já foram submetidos a ensaios de inibição enzimática, 25 apresentou seletividade para CK1?, com 40% de inibição. Para aqueles compostos com melhor potencial de inibição à concentração de 10 ?M será determinado o IC50 e uma extensa análise dos resultados será realizada futuramente. / Alzheimer\'s disease (AD) is a progressive neurodegenerative disorder characterized by loss of cortical and subcortical neurons. Pathological patterns of Alzheimer\'s disease include the presence of neurofibrillary lesions consisting of the accumulation of amyloid-? protein and the neurofibrillary tangles, resulting of hyperphosphorylated Tau protein. Only two major groups of drugs are used for treatment of AD, cholinesterase inhibitors and antagonists of Nmethyl- D-aspartate receptor. The phosphorylation of proteins by protein kinases constitute one of the major mechanisms which cells use to regulate their metabolism and imbalances in these activities are related to a series of diseases. The high number of isoforms of protein kinase 1 (CK1) found in AD and its association with neurodegenerative markers of indicate their participation in the final stages of degeneration, common to both AD and other neurodegenerative disorders. The approach of CK1 protein as a therapeutic target for AD is promising as the usual compounds used to reduce the production of amyloid-? also block the breakdown of other proteins, causing severe side effects. Increasingly, bioinformatics tools have been used as an aid in reducing costs and time to research. Among these techniques highlights the virtual screening, which includes a set of techniques used sequentially with the aim of select compounds prototypes for the desired target. Ligand and structure-based virtual screening techniches from a 500 thousand database resulted in 35 selected with inhibitory profile for CK1 enzyme were used in this study. The compounds 24, 25, 36, 39 41 and 42 had significan potential for CK1? enzyme inhibition. Among those submitted to enzyme inhibition assays, compound 25 showed selectivity for CK1? , with 40 % inhibition. For those compounds with the best inhibitory concentration at 10 mM and the IC50 will be given an extensive analysis of the results will be held in the future .

A doença de Chagas afeta milhões de pessoas e os fármacos existentes não são seguros e apresentam eficácia limitada. Muitos produtos naturais mostraram efeitos inibitórios contra uma enzima importante para a sobrevivência do Trypanosoma cruzi, a gliceraldeído-3-fosfato desidrogenase (GAPDH). Dentre esses produtos naturais destacam-se aqueles da classe dos flavonoides, sendo que um deles, o tilirosídeo, mostrou-se interessante por inibir a enzima com valores de IC50 e Ki iguais a 46 e 25 µM, respectivamente, além de ter sido eficaz contra a cepa do T. cruzi resistente a fármacos (cepa Y) mostrando um valor de IC50 igual a 770 µM. Com objetivo de identificar novos potenciais inibidores da TcGAPDH baseados no tilirosídeo foram empregados métodos computacionais nos quais combinaram-se duas diferentes estratégias: os ensaios virtuais baseados na estrutura do ligante (LBVS) e os ensaios virtuais baseados na estrutura do receptor (SBVS). Os compostos que se ajustaram ao sítio catalítico da enzima e preditos para interagir de forma efetiva com o alvo foram adquiridos e testados contra a TcGAPDH. Os estudos de inibição enzimática foram realizados utilizando as técnicas de calorimetria de titulação isotérmica e espectroscopia de fluorescência obtendo como resultados as constantes de inibição dos compostos selecionados e seus modos de inibição. Dois flavonoides, o Nequimed 214 e o Nequimed 215 inibiram a TcGAPDH na mesma grandeza que o composto de partida, o tilirosídeo, mas como possuem cerca da metade da massa molecular, houve grande aumento da eficiência do ligante. A partir dessa informação, foram selecionados uma segunda geração de compostos preditos a interagir com a TcGAPDH. Deste modo, foram adquiridos bioisósteros de flavonoides que foram testados contra essa enzima, sendo que dois dos mesmos mostraram-se ativos e com alta eficiência do ligante. Foram adquiridos também compostos pertencentes à classe das hidantoínas, rodaninas, tio-hidantoínas e pirrolidina-2,4-dionas sendo que muitos dos mesmos foram ativos e mostraram os maiores valores de eficiência do ligante já relatados para a TcGAPDH, tornando-os excelentes candidatos para otimização molecular. Os resultados obtidos sugerem que vários inibidores possuem inibição não competitiva com relação ao substrato G3P. Os inibidores mais potentes foram testados contra a GAPDH de humanos e não foi verificada seletividade relevante. / Chagas disease affects millions of people worldwide. The available drugs are not safe and show limited efficacy. Many natural products inhibit the glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an important Trypanosoma cruzi enzyme. Among them, flavonoids have stood out and one of them, the tiliroside, inhibited the enzyme with IC50 and Ki values of 46 and 25 µM, respectively. Furthermore, unpublished results showed that this compound was effective against the drug-resistant strain of T. cruzi (Y strain) with IC50 value of 770 µM. In order to select potential inhibitors of TcGAPDH based on the tiliroside structure, computational methods were used combining two different strategies, the ligand-based virtual screening (LBVS) and the structure-based virtual screening (SBVS). The compounds predicted to interact effectively with the target and fit into the active site of the enzyme were purchased and tested. Enzyme inhibition studies were performed using isothermal titration calorimetry and fluorescence spectroscopy from which the constants and mode of inhibition of the compounds were determined. Two of the tested flavonoids, Nequimed 214 and Nequimed 215, showed inhibition activity against TcGAPDH in the same magnitude values as the starting compound, the tiliroside, in spite of their lower molecular weight, thus greatly enhancing the ligand efficiency (LE). These data prompted us to search for some flavonoid bioisosters that were obtained and tested against this enzyme, and two of them proved to be active with high ligand efficiencies. We also purchased compounds belonging to the class of hydantoins, pyrrolidine-2,4-dione, thio-hydantoin and rhodanine. Many of them were active at low micromolar concentration range and exhibited the highest ligand efficiencies ever reported for this enzyme, therefore becoming excellent candidates for molecular optimization. The obtained results suggest that most of inhibitors tested behave as non-competitive inhibitors with respect to the G3P substrate. The most potent inhibitors were tested against human GAPDH and relevant selectivity was not observed.

De nombreuses études des RCPGs révèlent que leur activation n’implique pas que deux états conformationnels, l’un activé et l’autre inactivé, mais une diversité plus importante de ces états, impliquant également des états intermédiaires. Nous avons utilisé la simulation par dynamique moléculaire et l’analyse des interactions intramoléculaires non-covalentes pour étudier la plasticité structurale du récepteur CCR5 sous sa forme monomérique et dimérique. En couplant notre analyse avec diverses données expérimentales, nous avons pu proposer trois architectures dimériques du récepteur et associer des mouvements et des interactions clefs aux états conformationnels de CCR5 libre, lié à un agoniste, lié à un agoniste inverse et constitutivement activé ou inactivé par mutation d’acides aminés. Nous avons également développé une méthode d’identification des motifs d’interactions intramoléculaires transmembranaires, permettant de discriminer les états d’activations des RCPGs. / Many studies reveal that GPCR activation does not simply involve two conformational states, one activated and the other inactivated, but a variety of these states coupled to intermediate states. By using molecular dynamics simulations and analyzing non-covalent intramolecular interactions, we studied the structural plasticity of monomeric and dimeric CCR5. By coupling our analysis with various experimental data, we identified three dimeric organizations states of the receptor and associated key motions and intramolecular interactions to free CCR5, bound to an agonist, bound to an inverse agonist and constitutively activated or inactivated by mutated residues. We have also developed a method to identify intramolecular transmembrane interactions patterns, which allow the discrimination of GPCRs activation states.